Search
Search Results
-
Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy
BackgroundTumor-draining lymph nodes (TDLNs) are primary sites, where anti-tumor lymphocytes are primed to tumor-specific antigens and play pivotal...
-
Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing
BackgroundDendritic Cell Cytokine-induced killer cell (DC-CIK) coculture treatment in cancer immunotherapy has been shown to be effective. However,...
-
Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy
BackgroundActive targeting by surface-modified nanoplatforms enables a more precise and elevated accumulation of nanoparticles within the tumor,...
-
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is...
-
rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
BackgroundAutologous tumor cell-based vaccines (ATVs) aim to prevent and treat tumor metastasis by activating patient-specific tumor antigens to...
-
3D-Autologous Culture Method for Precision Oncology
The 3D-autologous culture method (3D-ACM) for patient-derived cancer samples utilizes a patient’s own body fluid or serum to prepare a 3D scaffold...
-
The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review
This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and...
-
Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy
BackgroundProstate cancer (PCa) is the second leading cause of cancer-related deaths among men worldwide. Immunotherapy is an emerging treatment...
-
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk...
-
Enhanced tumor control activities of anti-mPD-L1 antibody and antigen-presenting cell-like natural killer cell in an allograft model
BackgroundDespite the utilization of immune checkpoint inhibitors (ICIs) in treating numerous types of cancers being approved, their efficacy in...
-
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel...
-
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy,...
-
Synthetic-Based Tumor-Infiltrating Lymphocytes (TILs) in Adoptive Cell Therapies
Cancer is a complex microenvironment, characterized by dynamic reciprocal communication between tumor cells, tumor-associated immune cells, and other...
-
Unravelling immune microenvironment features underlying tumor progression in the single-cell era
The relationship between the immune cell and tumor occurrence and progression remains unclear. Profiling alterations in the tumor immune...
-
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This...
-
Insights into the tumor microenvironment of B cell lymphoma
The standard therapies in lymphoma have predominantly focused on targeting tumor cells with less of a focus on the tumor microenvironment (TME),...
-
Translational and structural vaccinomics approach to design a multi-epitope vaccine against NOL4 autologous antigen of small cell lung cancer
Small cell lung cancer (SCLC) is one of the most common cancers and it is the sixth common cause for cancer-related deaths. The high plasticity and...
-
Mouse Melanoma Model in Tumor Vaccines and Immunotherapy Research
Efficacy of novel cancer immunization protocols could be tested in cell line-derived xenograft tumor models (CDX), which are based on the...
-
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte...
-
MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation
BackgroundRelapse is a frequent occurrence in autologous hematopoietic stem cell transplantation (AHSCT), and early relapse after AHSCT results in...
